Development of Effective Therapeutics Targeting HER3 for Cancer Treatment.

Liu, Xiaolong; Liu, Shuang; Lyu, Hui; Riker, Adam I; Zhang, Yamin; Liu, Bolin

Liu, Xiaolong; Liu, Shuang; Lyu, Hui; Riker, Adam I; Zhang, Yamin; Liu, Bolin.

Afiliação

Liu X; 1Department of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin, China.
Liu S; 2Department of Genetics, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA USA.
Lyu H; 2Department of Genetics, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA USA.
Riker AI; 3Department of Surgery, Section of Surgical Oncology, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA USA.
Zhang Y; 1Department of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin, China.
Liu B; 2Department of Genetics, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA USA.

Biol Proced Online ; 21: 5, 2019.

Article em En | MEDLINE | ID: mdl-30930695

Palavras-chave

Cell signaling; Epigenetic approach; HER3; Targeted therapy; miRNA

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Biol Proced Online Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google